Standard Glass Lining Technology Ltd Q1 FY26 / FY25 – IPO Hangover, Pharma Pipelines, and P/E Higher than Your Exam Stress
1. At a Glance
Standard Glass Lining Technology Ltd (SGLTL) – the engineering equipment maker with a name so long it could be a LinkedIn job title – is trading at ₹181/share, a cool ₹3,611 Cr market cap. Stock P/E? A Bollywood-esque 51x, well above the industry’s 36x. ROE is a modest 11.6%, ROCE 16.5%, but hey, at least sales grew 13% YoY in FY25 to ₹645 Cr with PAT at ₹70 Cr. The IPO in Jan’25 raised ₹410 Cr, and since then the company’s order book is buzzing with pharma and chemical clients.
But wait — debtor days stretched to 127, working capital cycle ballooned to 272 days, and operating cash flow in FY25 was just ₹5 Cr. In other words, profit is visible on paper, but cash is hiding like your salary at the end of EMIs.
Question: Is this the next Kaynes Tech in the making, or will high valuations turn it into the “Yes Bank” of industrial equipment hype?
2. Introduction
Standard Glass is a 2012-born player in pharma and chemical equipment, now flexing itself among the top 5 specialized engineering equipment makers in India. In just 13 years, it went from being a niche reactor manufacturer to delivering 11,000+ units across pharma, chemicals, and biotech.
If you’ve ever seen a shiny glass-lined reactor in a pharma plant — that’s their bread and butter. And if you haven’t, just imagine a giant steel “pressure cooker” with glass lining, only it’s worth crores, not thousands.
The company went public in Jan 2025, collecting ₹410 Cr from the market. Since then, it’s been announcing partnerships faster than Bollywood celebrities announcing divorces: a 20-year tie-up with Japan’s AGI, a US subsidiary in South Carolina, and export pacts with Singapore and USA partners.
The market, drunk on IPO euphoria, gave it a 5.6x Price-to-Sales multiple, higher than most infra names. Clearly, investors are hoping this smallcap turns into the Kaynes/Honeywell of pharma equipment. But as always, execution is the difference between “market darling” and “market meme.”
3. Business Model – WTF Do They Even Do?
Lazy investor, here’s your crash course:
Reaction Systems → Fancy word for reactors. Glass-lined, stainless steel, nickel alloy. Pharma guys use these to cook APIs, not biryani.
Storage, Separation & Drying Systems → Tanks, dryers, ANFDs, RCVDs. Basically, drying powders and separating stuff without making a mess.
Plant Engineering & Services → Turnkey facility design, installation, commissioning. Think “EPC contractor” but only for pharma/chemicals.
PTFE-Lined Pipes → Pipes that can handle corrosive chemicals. Useful when your products can eat through regular steel faster than Mirchi Bajji through your stomach lining.
Heat Exchangers → Equipment to cool or heat stuff during distillation. New tie-up with AGI means they are eyeing a $2B global market.
Business split FY24:
Pharma 82%, Chemicals 13%, Others 6%.
By product → Reaction Systems 57%, Drying & Separation 30%, Services 13%.
So basically, they’re pharma’s hardware store — reactors, tanks, dryers, pipes — anything that isn’t a scientist in a lab coat.
